Teneliximab
Teneliximab is a chimeric monoclonal antibody[1] binding to the immune stimulatory protein CD40. As of 2009, it has not entered clinical trials.[2]
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Chimeric (mouse/human) |
| Target | CD40 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
  (what is this?) (verify) | |
References
- International Nonproprietary Names For Pharmaceutical Substances
- Iqbal S. Grewal, ed. (January 15, 2009). Therapeutic Targets of the TNF Superfamily (Advances in Experimental Medicine and Biology). Springer. p. 22. ISBN 978-0-387-89519-2.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.